LIVIVO - Search results -

Search results

Result 1 - 10 of total 13385

Search options

Article ; Online: Author Q&A: Lee Smith.

Smith, Lee

2020 Volume 228, Issue 5, Page(s) 343

Language	English
Publishing date	2020-03-13
Publishing country	England
Document type	Interview
ZDB-ID	218090-x
ISSN	1476-5373 ; 0007-0610
ISSN (online)	1476-5373
ISSN	0007-0610
DOI	10.1038/s41415-020-1403-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ul III Zs.143: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 447: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Audio / Video ; Online: Dr. Kelley Lee

Lee, Kelley / Johal, Am / Smith, Paige / Wong, Rachel / Feng, Kathy / Pinillos, Fiorella / SFU's Vancity Office of Community Engagement

The World Health Organization and COVID-19 — Below the Radar Conversations

2020

Abstract: ... is Dr. Kelley Lee, Canada Research Chair in Global Health Governance at Simon Fraser University ... Dr. Lee is trained in International Relations and Public Administration with a focus on international ... chaired the WHO Resource Group on Globalization, Trade and Health. Dr Lee also co-led a major ...

Abstract	Welcome to the first episode of our Below the Radar conversations series. Our first guest speaker is Dr. Kelley Lee, Canada Research Chair in Global Health Governance at Simon Fraser University. In this video, she chats with Am Johal about The World Health Organization and COVID-19. Note: This interview was recorded prior to the United States cutting funding to the WHO. Am Johal is the Director of SFU’s Vancity Office of Community Engagement, and the Co-Director of SFU’s Community-Engaged Research initiative. Dr. Lee is trained in International Relations and Public Administration with a focus on international political economy. She spent over twenty years at the London School of Hygiene and Tropical Medicine, initially analyzing the role of the UN in health. She was a core member of two major donor-led studies on WHO reform during the 1990s. She co-established the WHO Collaborating Centre on Global Change and Health, and chaired the WHO Resource Group on Globalization, Trade and Health. Dr Lee also co-led a major international initiative to secure public access to tobacco industry documents, and analyze their contents in relation to the globalization of the tobacco industry. She has authored over 100 peer reviewed papers, 50 book chapters and 13 books including Globalization and Health, An introduction (Palgrave Macmillan, 2003), The World Health Organization (Routledge, 2008), Global Health and International Relations (Polity Press with Colin McInnes, 2012), and Case Studies on Corporations and Global Health Governance (Rowman and Littlefield International with Nora Kenworthy and Ross MacKenzie, 2016). She joined the SFU Faculty of Health Sciences in 2011 as Associate Dean, Research and Director of Global Health. She is a Fellow of the Faculty of Public Health, Royal College of Physicians and Fellow of the Canadian Academy of Health Sciences.
Keywords	covid19
Subject code	306
Language	English
Publishing date	2020-04-21
Publishing country	ca
Document type	Audio / Video ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Comments on "Caffeine intake and cognitive functions in children by Zhang, Lee and Qiu".

Smith, Andrew P

Psychopharmacology

2021 Volume 238, Issue 3, Page(s) 913–915

MeSH term(s)	Caffeine ; Child ; Cognition ; Eating ; Humans
Chemical Substances	Caffeine (3G6A5W338E)
Language	English
Publishing date	2021-01-27
Publishing country	Germany
Document type	Letter ; Comment
ZDB-ID	130601-7
ISSN	1432-2072 ; 0033-3158
ISSN (online)	1432-2072
ISSN	0033-3158
DOI	10.1007/s00213-021-05775-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui I Zs.240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Lee Rubin: Our mentor and role model.

Bazenet, Chantal / Desmond, Howard / Frank, Eric / Doherty, Patrick / Eilers, Andreas / Gatchalian, Christine / Glicksman, Marcie / Graczyk, Piotr / Gusovsky, Fabian / Ham, Jonathan / Kaplan, David / Klymkoswsky, Michael / Kotkow, Karen / Krolewski, Richard / Lang, Paul / O'Neil, Alison Linsley / McCarthy, Mary Jane / Meiri, Karina / Miller, Freda /

Neumage, Monica Mota / Ozek, Ceren / Philpott, Karen / Piccinotti, Silvia / Price, Feodor / Raff, Martin / Ratcliffe, Marianne / Relton, Jane / Rhodes, Ken / Schwob, James / Smales, Caroline / Smith, Terrence / Spadoni, Cesare / Taylor, Joanne / Vekrellis, Kostas / Whitfield, Jonny

Science (New York, N.Y.)

2017 Volume 355, Issue 6327, Page(s) 806

Language	English
Publishing date	2017-02-24
Publishing country	United States
Document type	Letter
ZDB-ID	128410-1
ISSN	1095-9203 ; 0036-8075
ISSN (online)	1095-9203
ISSN	0036-8075
DOI	10.1126/science.aam8703
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 27: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 77: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Bayesian Population Forecasting: Extending the Lee-Carter Method.

Wiśniowski, Arkadiusz / Smith, Peter W F / Bijak, Jakub / Raymer, James / Forster, Jonathan J

Demography

2015 Volume 52, Issue 3, Page(s) 1035–1059

Abstract: ... populations by age and sex. The approach embeds the Lee-Carter type models for forecasting the age patterns ...

Abstract	In this article, we develop a fully integrated and dynamic Bayesian approach to forecast populations by age and sex. The approach embeds the Lee-Carter type models for forecasting the age patterns, with associated measures of uncertainty, of fertility, mortality, immigration, and emigration within a cohort projection model. The methodology may be adapted to handle different data types and sources of information. To illustrate, we analyze time series data for the United Kingdom and forecast the components of population change to the year 2024. We also compare the results obtained from different forecast models for age-specific fertility, mortality, and migration. In doing so, we demonstrate the flexibility and advantages of adopting the Bayesian approach for population forecasting and highlight areas where this work could be extended.
MeSH term(s)	Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Bayes Theorem ; Birth Rate/trends ; Child ; Child, Preschool ; Emigration and Immigration/trends ; Female ; Forecasting/methods ; Humans ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Models, Statistical ; Mortality/trends ; Population Dynamics ; Sex Factors ; United Kingdom ; Young Adult
Language	English
Publishing date	2015-06
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	280612-5
ISSN	1533-7790 ; 0070-3370
ISSN (online)	1533-7790
ISSN	0070-3370
DOI	10.1007/s13524-015-0389-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 1487: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease

Sarah Scobie / Sue Jowett / Tosin Lambe / Smitaa Patel / Rebecca Woolley / Natalie Ives / Caroline Rick / Christina Smith / Marion C Brady / Carl Clarke / Cath Sackley

Pilot and Feasibility Studies, Vol 7, Iss 1, Pp 1-

preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial

2021 Volume 11

Abstract: Abstract Background The PD COMM pilot randomised controlled trial compared Lee Silverman Voice ...

Abstract	Abstract Background The PD COMM pilot randomised controlled trial compared Lee Silverman Voice Treatment (LSVT® LOUD) with standard NHS speech and language therapy (SLT) and a control arm in people with Parkinson’s disease (PwPD) with self-reported problems with voice or speech. This analysis compares costs and quality of life outcomes between the trial arms, and considers the validity of the alternative outcome measures for economic evaluations. Methods A comparison of costs and outcomes was undertaken alongside the PD COMM pilot trial involving three arms: LSVT® LOUD treatment (n = 30); standard NHS SLT (n = 30); and a control arm (n = 29) excluded from receiving therapy for at least 6 months after randomisation unless deemed medically necessary. For all trial arms, resource use and NHS, social care and patient costs and quality of life were collected prospectively at baseline, 3, 6, and 12 months. Total economic costs and outcomes (EQ-5D-3L, ICECAP-O) were considered over the 12-month follow-up period from an NHS payer perspective. Quality of life measures for economic evaluation of SLT for people with Parkinson’s disease were compared. Results Whilst there was no difference between arms in voice or quality of life outcomes at 12 months, there were indications of differences at 3 months in favour of SLT, which need to be confirmed in the main trial. The estimated mean cost of NHS care was £3288 per patient per year for the LSVT® LOUD arm, £2033 for NHS SLT, and £1788 for the control arm. EQ-5D-3L was more strongly correlated to voice impairment than ICECAP-O, and was sensitive to differences in voice impairment between arms. Conclusions The pilot did not identify an effect of SLT on disease-specific or economic outcomes for PwPD at 12 months; however, there appeared to be improvements at 3 months. In addition to the sample size not powered to detect difference in cost-consequence analysis, many patients in the control arm started SLT during the 12-month period used for economic analysis, in line with the study protocol. The LSVT® LOUD intervention was more intense and therefore more costly. Early indications suggest that the preferred economic outcome measure for the full trial is EQ-5D-3L; however, the ICECAP-O should still be included to capture a broader measure of wellbeing. Trial registration International Standard Randomised Controlled Trial Number Register: ISRCTN75223808. Registered 22 March 2012.
Keywords	Parkinson’s disease ; Pilot randomised controlled trial ; Speech and language therapy ; Cost-consequence analysis ; Medicine (General) ; R5-920
Language	English
Publishing date	2021-08-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.

Scobie, Sarah / Jowett, Sue / Lambe, Tosin / Patel, Smitaa / Woolley, Rebecca / Ives, Natalie / Rick, Caroline / Smith, Christina / Brady, Marion C / Clarke, Carl / Sackley, Cath

Pilot and feasibility studies

2021 Volume 7, Issue 1, Page(s) 154

Abstract: Background: The PD COMM pilot randomised controlled trial compared Lee Silverman Voice Treatment ...

Abstract	Background: The PD COMM pilot randomised controlled trial compared Lee Silverman Voice Treatment (LSVT® LOUD) with standard NHS speech and language therapy (SLT) and a control arm in people with Parkinson's disease (PwPD) with self-reported problems with voice or speech. This analysis compares costs and quality of life outcomes between the trial arms, and considers the validity of the alternative outcome measures for economic evaluations. Methods: A comparison of costs and outcomes was undertaken alongside the PD COMM pilot trial involving three arms: LSVT® LOUD treatment (n = 30); standard NHS SLT (n = 30); and a control arm (n = 29) excluded from receiving therapy for at least 6 months after randomisation unless deemed medically necessary. For all trial arms, resource use and NHS, social care and patient costs and quality of life were collected prospectively at baseline, 3, 6, and 12 months. Total economic costs and outcomes (EQ-5D-3L, ICECAP-O) were considered over the 12-month follow-up period from an NHS payer perspective. Quality of life measures for economic evaluation of SLT for people with Parkinson's disease were compared. Results: Whilst there was no difference between arms in voice or quality of life outcomes at 12 months, there were indications of differences at 3 months in favour of SLT, which need to be confirmed in the main trial. The estimated mean cost of NHS care was £3288 per patient per year for the LSVT® LOUD arm, £2033 for NHS SLT, and £1788 for the control arm. EQ-5D-3L was more strongly correlated to voice impairment than ICECAP-O, and was sensitive to differences in voice impairment between arms. Conclusions: The pilot did not identify an effect of SLT on disease-specific or economic outcomes for PwPD at 12 months; however, there appeared to be improvements at 3 months. In addition to the sample size not powered to detect difference in cost-consequence analysis, many patients in the control arm started SLT during the 12-month period used for economic analysis, in line with the study protocol. The LSVT® LOUD intervention was more intense and therefore more costly. Early indications suggest that the preferred economic outcome measure for the full trial is EQ-5D-3L; however, the ICECAP-O should still be included to capture a broader measure of wellbeing. Trial registration: International Standard Randomised Controlled Trial Number Register: ISRCTN75223808. Registered 22 March 2012.
Language	English
Publishing date	2021-08-09
Publishing country	England
Document type	Journal Article
ZDB-ID	2809935-7
ISSN	2055-5784
ISSN	2055-5784
DOI	10.1186/s40814-021-00888-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Internal lee waves and baroclinic bores over a tropical seamount shark ‘hot-spot’

Hosegood, P.J / A.S. Brierley / K. Adams / R. Proud / W.A.M. Nimmo-Smith

Progress in oceanography. 2019 Jan. 22,

2019

Abstract: ... oscillations result from internal lee waves with 30 m vertical wavelength generated by the prevailing currents ... from the lee waves due to the abrupt transition from steeply sloping sides to a relatively flat summit ... lee waves as the dynamic mechanism of leading order importance to the previously observed accumulation ...

Abstract	Oceanographic observations were made with a subsurface oceanographic mooring over the summit and flanks of two neighbouring seamounts in the tropical Indian Ocean to identify processes that may be responsible for the aggregation of silvertip sharks (Carcharhinus albimarginatus) in the deep water drop-off surrounding the summits. The seamounts, which are in the Chagos Archipelago in the British Indian Ocean Territories, are narrow in horizontal extent (<10 km), have steeply sloping (>15°) sides that rise from depths of >600 m, and flat summits at a depth of 70 m. They are subjected to forcing at subinertial, basin-scales and local scales that include a mixed tidal regime and storm-generated near inertial waves. At the drop-off, at a depth of between 70 – 100 m, isotherms oscillate at both diurnal and semidiurnal frequencies with amplitudes of ∼20-30 m. The waves of tidal origin are accompanied by short period (∼5 minutes) internal waves with amplitudes O(10 m) and frequencies close to the local buoyancy frequency, N, within the thermocline which is the maximum frequency possible for freely propagating internal waves. The tidal oscillations result from internal lee waves with 30 m vertical wavelength generated by the prevailing currents over the supercritical seamount flanks, whereby the bottom slope is greater than the internal tide wave slope. The ‘near-N’ waves are due to enhanced shear associated with the hydraulic jumps that form from the lee waves due to the abrupt transition from steeply sloping sides to a relatively flat summit. The jumps manifest themselves as bottom-trapped bores that propagate up the slope towards the summit. Further observations over the summit reveal that the bores subsequently flush the summits with cold water with tidal periodicity. The bores, which have long wave phase speeds more than double that of the bore particle velocities, are characterised by intense vertical velocities (>0.1 m s-1) and inferred local resuspension but relatively little turbulence based on temperature overturns. Our results strongly implicate lee waves as the dynamic mechanism of leading order importance to the previously observed accumulation of biomass adjacent to the supercritical slopes that are commonplace throughout the archipelago. We propose that further investigation should identify the spatiotemporal correlation between internal wave activity and fish schooling around the summit, and whether such schooling attracts predators.
Keywords	biomass ; Carcharhinus ; cold ; periodicity ; predators ; seamounts ; sharks ; temperature ; tides ; turbulent flow ; water ; wavelengths ; Indian Ocean
Language	English
Dates of publication	2019-0122
Size	p. .
Publishing place	Elsevier Ltd
Document type	Article
Note	Pre-press version
ISSN	0079-6611
DOI	10.1016/j.pocean.2019.01.010
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease

Catherine M. Sackley / Christina H. Smith / Caroline E. Rick / Marian C. Brady / Natalie Ives / Smitaa Patel / Rebecca Woolley / Francis Dowling / Ramilla Patel / Helen Roberts / Sue Jowett / Keith Wheatley / Debbie Kelly / Gina Sands / Carl E. Clarke / on behalf of the PD COMM Pilot Collaborative Group

Pilot and Feasibility Studies, Vol 4, Iss 1, Pp 1-

a pilot randomised controlled trial (PD COMM pilot)

2018 Volume 10

Abstract: ... little evidence for the effectiveness of standard speech and language therapy (SLT) or Lee Silverman ...

Abstract	Abstract Background Speech-related problems are common in Parkinson’s disease (PD), but there is little evidence for the effectiveness of standard speech and language therapy (SLT) or Lee Silverman Voice Treatment (LSVT LOUD®). Methods The PD COMM pilot was a three-arm, assessor-blinded, randomised controlled trial (RCT) of LSVT LOUD®, SLT and no intervention (1:1:1 ratio) to assess the feasibility and to inform the design of a full-scale RCT. Non-demented patients with idiopathic PD and speech problems and no SLT for speech problems in the past 2 years were eligible. LSVT LOUD® is a standardised regime (16 sessions over 4 weeks). SLT comprised individualised content per local practice (typically weekly sessions for 6–8 weeks). Outcomes included recruitment and retention, treatment adherence, and data completeness. Outcome data collected at baseline, 3, 6, and 12 months included patient-reported voice and quality of life measures, resource use, and assessor-rated speech recordings. Results Eighty-nine patients were randomised with 90% in the therapy groups and 100% in the control group completing the trial. The response rate for Voice Handicap Index (VHI) in each arm was ≥ 90% at all time-points. VHI was highly correlated with the other speech-related outcome measures. There was a trend to improvement in VHI with LSVT LOUD® (difference at 3 months compared with control: − 12.5 points; 95% CI − 26.2, 1.2) and SLT (difference at 3 months compared with control: − 9.8 points; 95% CI − 23.2, 3.7) which needs to be confirmed in an adequately powered trial. Conclusion Randomisation to a three-arm trial of speech therapy including a no intervention control is feasible and acceptable. Compliance with both interventions was good. VHI and other patient-reported outcomes were relevant measures and provided data to inform the sample size for a substantive trial. Trial registration International Standard Randomised Controlled Trial Number Register: ISRCTN75223808 . registered 22 March 2012.
Keywords	Parkinson’s disease ; Pilot randomised controlled trial ; Speech and language therapy ; Medicine (General) ; R5-920
Subject code	410
Language	English
Publishing date	2018-01-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.

Sackley, C M / Rick, C / Au, P / Brady, M C / Beaton, G / Burton, C / Caulfield, M / Dickson, S / Dowling, F / Hughes, M / Ives, N / Jowett, S / Masterson-Algar, P / Nicoll, A / Patel, S / Smith, C H / Woolley, R / Clarke, C E

Trials

2020 Volume 21, Issue 1, Page(s) 436

Abstract: ... available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is ...

Abstract	Background: Parkinson's disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals' needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson's Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016.
MeSH term(s)	Clinical Trials, Phase III as Topic ; Cost-Benefit Analysis ; Humans ; Language Therapy/methods ; Multicenter Studies as Topic ; Parkinson Disease/complications ; Quality of Life ; Randomized Controlled Trials as Topic ; Speech Therapy/methods ; Surveys and Questionnaires ; United Kingdom ; Voice ; Voice Disorders/etiology ; Voice Disorders/rehabilitation
Language	English
Publishing date	2020-05-27
Publishing country	England
Document type	Clinical Trial Protocol ; Comparative Study ; Journal Article
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1745-6215
ISSN (online)	1745-6215
ISSN	1468-6694 ; 1745-6215
DOI	10.1186/s13063-020-04354-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito